A Single-arm, Open-label, Multicenter Study of Enfortumab Vedotin (ASG-22CE) for Treatment of Patients With Locally Advanced or Metastatic Urothelial Cancer Who Previously Received Immune Checkpoint Inhibitor (CPI) Therapy

Trial Profile

A Single-arm, Open-label, Multicenter Study of Enfortumab Vedotin (ASG-22CE) for Treatment of Patients With Locally Advanced or Metastatic Urothelial Cancer Who Previously Received Immune Checkpoint Inhibitor (CPI) Therapy

Recruiting
Phase of Trial: Phase II

Latest Information Update: 04 Dec 2017

At a glance

  • Drugs Enfortumab vedotin (Primary)
  • Indications Bladder cancer; Urethral cancer; Urogenital cancer
  • Focus Registrational; Therapeutic Use
  • Sponsors Astellas Pharma; Seattle Genetics
  • Most Recent Events

    • 10 Oct 2017 According to an Astellas Pharma media release, Data from this trial will support potential registration under the U.S. Food and Drug Administration's (FDA) accelerated approval regulations.
    • 10 Oct 2017 According to an Astellas Pharma media release, first patient has been dosed.
    • 02 Oct 2017 Status changed from planning to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top